Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030173

Enrollment

Unknown

Registered

2020-02-24

Start date

2020-02-17

Completion date

Unknown

Last updated

2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Experimental group:umbilical cord mesenchymal stem cells

control group:convention treatment

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-60 years old; 2. Patients with clinical symptoms, signs, auxiliary detection combined with 1 or more nucleic acid test to confirm the diagnosis of new coronavirus pneumonia; 3. Voluntarily sign the informed consent to comply with the requirements of the program.

Exclusion criteria

Exclusion criteria: 1. History of tumor; 2. Vascular embolism and pulmonary hypertension; 3. Suspected or established history of alcohol, drug or drug abuse; 4. Female patients of child-bearing age who are pregnant, breast-feeding or have a recent family planning; 5. Patients who have participated in or are participating in other drug trials within one month; 6. Patients considered unfit to participate in this clinical trial.

Design outcomes

Primary

Measure	Time frame
pulmonary function;Novel coronavirus pneumonic nucleic acid test;	—

Secondary

Measure	Time frame
pulmonary CT;pulmonary CT;chest radiography;	—

Countries

China

Contacts

Public ContactXue Zhigang

Hu'nan Yuanpin Cell Biotechnology Co., Ltd

xuezg@tongji.edu.cn+86 15000285942

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026